Results 171 to 180 of about 24,285 (193)

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Nature Medicine, 2022
Andreas Mackensen, Fabian Müller, Dimitrios Mougiakakos   +2 more
exaly  

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Lancet, The, 2023
Michelle A Petri, Thomas Dörner, Yoshiya Tanaka   +2 more
exaly  

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Lancet, The, 2011
Sandra V Navarra, Roger Levy, Ho-Youn Kim   +2 more
exaly  

Juvenile systemic lupus erythematosus

2009
openaire   +1 more source

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Lancet, The, 2018
Daniel J Wallace, Richard A Furie, Yoshiya Tanaka   +2 more
exaly  

Systemic lupus erythematosus

Lancet, The, 2007
Munther A Khamashta, David D'Cruz
exaly  

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet, The, 2018
Ronald F Van Vollenhoven, George C Tsokos, Peter E Lipsky   +2 more
exaly  

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Lancet, The, 2018
Zhi-wei Lai, Stephen Faraone, Andras Perl   +2 more
exaly  

Systemic lupus erythematosus

Nature Reviews Disease Primers, 2016
Arvind Kaul, Caroline Gordon, Mary K Crow   +2 more
exaly  

Systemic Lupus Erythematosus and Juvenile Dermatomyositis

2005
Murray H. Passo, Paul Rosen
openaire   +1 more source